USFDA concludes two pre approval inspections of Biocon's facilities in Bengaluru

18 Feb 2019 Evaluate

The US Food and Drug Administration (USFDA) has concluded two pre approval inspections of Biocon's manufacturing facilities in Bengaluru. There were no observations and no form 483 was issued after the pre-approval inspection of Biocon's Oral Solid Dosage Facility conducted between February 11-15, 2019.

The pre-approval inspection of the company's additional, new injectable manufacturing line for a biologic drug product, conducted between February 7-15, 2019, resulted in a form 483 with two observations. Biocon intends to address these expeditiously.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

360.85 -9.25 (-2.50%)
30-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1757.35
Dr. Reddys Lab 1254.65
Cipla 1223.05
Zydus Lifesciences 871.20
Lupin 2312.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×